|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
ES2751386T3
(es)
*
|
2011-12-21 |
2020-03-31 |
Amgen Inc |
Polipéptidos Fc variantes con unión potenciada al receptor de Fc neonatal
|
|
CN105051069B
(zh)
|
2013-01-14 |
2019-12-10 |
Xencor股份有限公司 |
新型异二聚体蛋白
|
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9212225B1
(en)
|
2014-07-01 |
2015-12-15 |
Amphivena Therapeutics, Inc. |
Bispecific CD33 and CD3 binding proteins
|
|
ES2743809T3
(es)
|
2014-07-31 |
2020-02-20 |
Amgen Res Munich Gmbh |
Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados
|
|
UY36245A
(es)
*
|
2014-07-31 |
2016-01-29 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
|
WO2016019969A1
(en)
|
2014-08-08 |
2016-02-11 |
Ludwig-Maximilians-Universität München |
Subcutaneously administered bispecific antibodies for use in the treatment of cancer
|
|
US20170306044A1
(en)
*
|
2014-10-09 |
2017-10-26 |
Engmab Ag |
Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
|
|
RU2753902C2
(ru)
|
2014-11-20 |
2021-08-24 |
Ф.Хоффманн-Ля Рош Аг |
Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1
|
|
BR112017010513A2
(pt)
*
|
2014-11-20 |
2018-04-03 |
F. Hoffmann-La Roche Ag |
?cadeias leves comuns e métodos de uso?
|
|
RS61010B1
(sr)
*
|
2014-11-20 |
2020-11-30 |
Hoffmann La Roche |
Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
|
|
CA2967426A1
(en)
|
2014-11-26 |
2016-06-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and tumor antigens
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
BR112017011166A2
(pt)
|
2014-11-26 |
2018-02-27 |
Xencor, Inc. |
anticorpos heterodiméricos que se ligam a cd3 e cd38
|
|
AU2015358325A1
(en)
*
|
2014-12-05 |
2017-05-25 |
Genentech, Inc. |
Anti-CD79b antibodies and methods of use
|
|
WO2016094881A2
(en)
*
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
|
AU2015364396B2
(en)
|
2014-12-19 |
2018-08-09 |
Alkermes, Inc. |
Single chain Fc fusion proteins
|
|
MY191964A
(en)
|
2015-01-23 |
2022-07-21 |
Sanofi Sa |
Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
|
|
EP3253790A4
(en)
|
2015-02-06 |
2018-07-25 |
University of Maryland, Baltimore |
Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection
|
|
TWI772258B
(zh)
|
2015-04-17 |
2022-08-01 |
德商安美基研究（慕尼黑）公司 |
Ｃｄｈ３與ｃｄ３之雙特異性抗體構築體
|
|
ES2889906T3
(es)
*
|
2015-05-21 |
2022-01-14 |
Harpoon Therapeutics Inc |
Proteínas de unión triespecíficas y usos médicos
|
|
EA201792581A1
(ru)
*
|
2015-05-29 |
2018-07-31 |
Амфивена Терапьютикс, Инк. |
Способы применения биспецифических cd33- и cd3- связывающих белков
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
FR3038517B1
(fr)
*
|
2015-07-06 |
2020-02-28 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Utilisation de fragments fc modifies en immunotherapie
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究（慕尼黑）公司 |
Dll3及cd3抗體構築體
|
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究（慕尼黑）公司 |
Ｃｄ７０及ｃｄ３抗體構築體
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
JO3620B1
(ar)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
TN2018000266A1
(en)
|
2016-02-03 |
2020-01-16 |
Amgen Res Munich Gmbh |
Psma and cd3 bispecific t cell engaging antibody constructs.
|
|
IL313507A
(en)
|
2016-02-03 |
2024-08-01 |
Amgen Res Munich Gmbh |
Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof
|
|
GB201604458D0
(en)
|
2016-03-16 |
2016-04-27 |
Immatics Biotechnologies Gmbh |
Peptides and combination of peptides for use in immunotherapy against cancers
|
|
PL3433280T3
(pl)
|
2016-03-22 |
2023-07-31 |
F. Hoffmann-La Roche Ag |
Dwuswoiste cząsteczki limfocytów T aktywowane przez proteazy
|
|
SG11201808085WA
(en)
*
|
2016-03-22 |
2018-10-30 |
Hoffmann La Roche |
Protease-activated t cell bispecific molecules
|
|
JOP20170091B1
(ar)
*
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
|
PT3461261T
(pt)
|
2016-05-20 |
2025-07-31 |
Harpoon Therapeutics Inc |
Proteínas de ligação ao cd3 de fragmento variável de cadeia única
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
CA3024723A1
(en)
|
2016-05-20 |
2017-11-23 |
Robert B. Dubridge |
Single domain serum albumin binding protein
|
|
TW201831513A
(zh)
|
2016-06-20 |
2018-09-01 |
Ｆ星貝塔有限公司 |
結合物件(一)
|
|
EP3474884A4
(en)
|
2016-06-22 |
2020-08-19 |
Alkermes, Inc. |
COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNOSTIMULANT AND ANTI-INFLAMMATORY PROPERTIES OF IL-10
|
|
MX2018016265A
(es)
|
2016-06-28 |
2019-07-04 |
Xencor Inc |
Anticuerpos heterodimericos que se unen al receptor 2 de somatostatina.
|
|
EP3544997A4
(en)
|
2016-11-23 |
2020-07-01 |
Harpoon Therapeutics, Inc. |
PROSTATE SPECIFIC MEMBRANE ANTIGEN BINDING PROTEIN
|
|
KR20190087539A
(ko)
|
2016-11-23 |
2019-07-24 |
하푼 테라퓨틱스, 인크. |
Psma 표적화 삼중특이성 단백질 및 사용 방법
|
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
|
US11535668B2
(en)
|
2017-02-28 |
2022-12-27 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
AU2018261951B2
(en)
|
2017-05-05 |
2025-05-22 |
Amgen Inc. |
Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
|
|
CN115028727A
(zh)
*
|
2017-05-12 |
2022-09-09 |
哈普恩治疗公司 |
靶向msln的三特异性蛋白质及使用方法
|
|
BR112019023855B1
(pt)
|
2017-05-12 |
2021-11-30 |
Harpoon Therapeutics, Inc |
Proteínas de ligação à mesotelina
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
JP7084990B2
(ja)
|
2017-10-13 |
2022-06-15 |
ハープーン セラピューティクス，インク． |
三重特異性タンパク質と使用方法
|
|
AU2018347607B2
(en)
|
2017-10-14 |
2025-08-21 |
Cytomx Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
|
KR20200085828A
(ko)
|
2017-11-08 |
2020-07-15 |
젠코어 인코포레이티드 |
신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
|
|
TWI827570B
(zh)
|
2017-12-11 |
2024-01-01 |
美商安進公司 |
雙特異性抗體產品之連續製造製程
|
|
EP4495142A3
(en)
|
2017-12-22 |
2025-05-07 |
Argenx BVBA |
Bispecific antigen binding construct
|
|
CN109957026A
(zh)
*
|
2017-12-22 |
2019-07-02 |
成都恩沐生物科技有限公司 |
共价多特异性抗体
|
|
UY38041A
(es)
|
2017-12-29 |
2019-06-28 |
Amgen Inc |
Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
|
|
GB201802487D0
(en)
|
2018-02-15 |
2018-04-04 |
Argenx Bvba |
Cytokine combination therapy
|
|
EP3773911A2
(en)
|
2018-04-04 |
2021-02-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
CN108610417B
(zh)
*
|
2018-04-28 |
2021-01-26 |
暨南大学 |
抗破伤风毒素中和抗体、其制备方法及用途
|
|
WO2019222283A1
(en)
|
2018-05-14 |
2019-11-21 |
Harpoon Therapeutics, Inc. |
Binding moiety for conditional activation of immunoglobulin molecules
|
|
GB201811404D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-CD137 Antibodies
|
|
US12344672B2
(en)
|
2018-07-12 |
2025-07-01 |
Invox Pharma Limited |
Antibody molecules that bind PD-L1 and CD137
|
|
GB201811450D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
|
GB201811415D0
(en)
*
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-Mesothelin Anti bodies
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
MX2021000399A
(es)
|
2018-07-12 |
2021-05-27 |
F Star Therapeutics Ltd |
Moleculas de anticuerpo que se unen a cd137 y ox40.
|
|
MX2021001221A
(es)
|
2018-07-30 |
2021-06-23 |
Amgen Res Munich Gmbh |
Administración prolongada de un constructo de anticuerpo biespecífico que se une a cd33 y cd3.
|
|
JP2021532073A
(ja)
|
2018-07-31 |
2021-11-25 |
アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｂｃｍａ−ｃｄ３二重特異性抗体のための投与レジメン
|
|
IL280467B2
(en)
|
2018-08-03 |
2025-03-01 |
Amgen Res Munich Gmbh |
Antibody constructs for CLDN18.2 and CD3
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
CN113286817B
(zh)
|
2018-09-25 |
2025-01-28 |
哈普恩治疗公司 |
Dll3结合蛋白及使用方法
|
|
BR112021005669A2
(pt)
|
2018-09-28 |
2021-06-22 |
Amgen Inc. |
anticorpos contra bcma solúvel
|
|
AU2019356564A1
(en)
|
2018-10-11 |
2021-04-29 |
Amgen Inc. |
Downstream processing of bispecific antibody constructs
|
|
JP7601760B2
(ja)
|
2018-10-23 |
2024-12-17 |
アムジエン・インコーポレーテツド |
リアルタイム予測のためのラマン分光モデルの自動校正及び自動保守
|
|
CN113795508A
(zh)
*
|
2018-12-24 |
2021-12-14 |
赛诺菲 |
具有突变型Fab结构域的多特异性结合蛋白
|
|
TWI871300B
(zh)
|
2019-01-28 |
2025-02-01 |
美商安進公司 |
藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
|
|
CN113784732B
(zh)
|
2019-05-07 |
2024-03-22 |
亘喜生物科技（上海）有限公司 |
靶向bcma的工程化免疫细胞及其用途
|
|
US12516128B2
(en)
|
2019-05-14 |
2026-01-06 |
Harpoon Therapeutics, Inc. |
EpCAM binding proteins and methods of use
|
|
EP3983520A1
(en)
|
2019-06-13 |
2022-04-20 |
Amgen, Inc |
Automated biomass-based perfusion control in the manufacturing of biologics
|
|
CN116987197A
(zh)
*
|
2019-06-20 |
2023-11-03 |
成都恩沐生物科技有限公司 |
共价多特异性抗体
|
|
US20210032370A1
(en)
|
2019-08-02 |
2021-02-04 |
Immatics Biotechnologies Gmbh |
Recruiting agent further binding an mhc molecule
|
|
DE102019121007A1
(de)
|
2019-08-02 |
2021-02-04 |
Immatics Biotechnologies Gmbh |
Antigenbindende Proteine, die spezifisch an MAGE-A binden
|
|
CA3152946A1
(en)
|
2019-09-10 |
2021-03-18 |
Amgen Inc. |
Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity
|
|
US20220389099A1
(en)
|
2019-11-04 |
2022-12-08 |
Amgen Inc. |
Methods for treating leukemia
|
|
DK3819007T3
(da)
|
2019-11-11 |
2024-09-30 |
Amgen Res Munich Gmbh |
Doseringsplan for anti-bcma-midler
|
|
EP4058485A1
(en)
|
2019-11-13 |
2022-09-21 |
Amgen Inc. |
Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
|
|
PT4065585T
(pt)
|
2019-11-25 |
2025-09-30 |
Alkermes Inc |
Compostos macrocíclicos substituídos e métodos de tratamento relacionados
|
|
AU2020405230A1
(en)
|
2019-12-20 |
2022-06-23 |
Amgen Inc. |
Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors
|
|
EP4090365A1
(en)
|
2020-01-15 |
2022-11-23 |
Immatics Biotechnologies GmbH |
Antigen binding proteins specifically binding prame
|
|
US20230093169A1
(en)
|
2020-01-22 |
2023-03-23 |
Amgen Research (Munch) Gmbh |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
|
WO2021158469A1
(en)
|
2020-02-03 |
2021-08-12 |
Amgen Inc. |
Multivariate bracketing approach for sterile filter validation
|
|
TWI888487B
(zh)
|
2020-02-14 |
2025-07-01 |
日商協和麒麟股份有限公司 |
與ｃｄ３結合之雙特異性抗體
|
|
IL295448A
(en)
|
2020-02-21 |
2022-10-01 |
Harpoon Therapeutics Inc |
flt3 binding proteins and methods of use
|
|
EP4118113A1
(en)
|
2020-03-12 |
2023-01-18 |
Amgen Inc. |
Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
|
|
CA3175275A1
(en)
|
2020-03-19 |
2021-09-23 |
Amgen Inc. |
Antibodies against mucin 17 and uses thereof
|
|
EP4149632A1
(en)
*
|
2020-05-14 |
2023-03-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind msln and cd3
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
EP4153633A1
(en)
|
2020-05-19 |
2023-03-29 |
Amgen Inc. |
Mageb2 binding constructs
|
|
CA3183693A1
(en)
|
2020-05-29 |
2021-12-02 |
Amgen Inc. |
Adverse effects-mitigating administration of a bispecific construct binding to cd33 and cd3
|
|
TWI852680B
(zh)
|
2020-06-19 |
2024-08-11 |
瑞士商赫孚孟拉羅股份公司 |
與 cd3 及 cd19 結合之抗體
|
|
KR20230057351A
(ko)
|
2020-08-27 |
2023-04-28 |
각코우호우진 쥰텐도 |
항절단형 변이 calr-cd3 이중특이성 항체 및 의약 조성물
|
|
WO2022060878A1
(en)
|
2020-09-16 |
2022-03-24 |
Amgen Inc. |
Methods for treating prostate cancer
|
|
EP4214233A1
(en)
|
2020-09-16 |
2023-07-26 |
Amgen Inc. |
Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
|
|
MX2023005197A
(es)
|
2020-11-06 |
2023-05-16 |
Amgen Inc |
Dominio de union a antigeno con tasa de recorte reducida.
|
|
CN116323671A
(zh)
|
2020-11-06 |
2023-06-23 |
安进公司 |
具有增加的选择性的多靶向性双特异性抗原结合分子
|
|
EP4240767A1
(en)
|
2020-11-06 |
2023-09-13 |
Amgen Inc. |
Polypeptide constructs binding to cd3
|
|
AU2021374036A1
(en)
|
2020-11-06 |
2023-06-08 |
Amgen Inc. |
Polypeptide constructs selectively binding to cldn6 and cd3
|
|
TW202233682A
(zh)
|
2020-11-10 |
2022-09-01 |
美商安進公司 |
用於投與ＢＣＭＡｘＣＤ３結合分子之方法
|
|
US11760747B2
(en)
|
2020-12-21 |
2023-09-19 |
Alkermes, Inc. |
Substituted piperidino compounds and related methods of treatment
|
|
CA3212665A1
(en)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
KR20230154311A
(ko)
|
2021-03-10 |
2023-11-07 |
젠코어 인코포레이티드 |
Cd3 및 gpc3에 결합하는 이종이량체 항체
|
|
CA3208770A1
(en)
|
2021-03-10 |
2022-09-15 |
Amgen Inc. |
Parallel chromatography systems and methods
|
|
CN117043173A
(zh)
|
2021-03-10 |
2023-11-10 |
美国安进公司 |
重组蛋白的纯化方法
|
|
EP4314075A4
(en)
*
|
2021-03-24 |
2025-04-09 |
Twist Bioscience Corporation |
VARIANT NUCLEIC ACID BANKS FOR CD3
|
|
EP4314078A1
(en)
|
2021-04-02 |
2024-02-07 |
Amgen Inc. |
Mageb2 binding constructs
|
|
CA3215049A1
(en)
*
|
2021-04-10 |
2022-10-13 |
Baiteng ZHAO |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
AU2022270361A1
(en)
|
2021-05-05 |
2023-11-16 |
Immatics Biotechnologies Gmbh |
Antigen binding proteins specifically binding prame
|
|
US20240384006A1
(en)
|
2021-05-06 |
2024-11-21 |
Amgen Research (Munich) Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
|
UY39967A
(es)
|
2021-10-06 |
2023-05-15 |
Immatics Biotechnologies Gmbh |
Indicaciones para los aglutinantes anti-PRAME
|
|
AR127458A1
(es)
|
2021-10-27 |
2024-01-24 |
Amgen Inc |
Predicción basada en aprendizaje profundo usando espectroscopia
|
|
KR20240099382A
(ko)
|
2021-11-03 |
2024-06-28 |
아피메트 게엠베하 |
이중특이적 cd16a 결합제
|
|
MX2024005397A
(es)
|
2021-11-03 |
2024-05-23 |
Affimed Gmbh |
Agentes de union a cd16a biespecificos.
|
|
US20230192886A1
(en)
|
2021-11-08 |
2023-06-22 |
Immatics Biotechnologies Gmbh |
Adoptive cell therapy combination treatment and compositions thereof
|
|
EP4483899A1
(en)
|
2022-02-25 |
2025-01-01 |
Juntendo Educational Foundation |
Medicine comprising combination of anti-mutant-calr antibody and another drug
|
|
WO2023209124A1
(en)
|
2022-04-29 |
2023-11-02 |
Immatics Biotechnologies Gmbh |
Mammalian display platform for multispecific antigen binding proteins
|
|
EP4522651A1
(en)
|
2022-05-12 |
2025-03-19 |
Amgen Research (Munich) GmbH |
Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
|
|
CA3258438A1
(en)
*
|
2022-06-30 |
2024-01-04 |
Modex Therapeutics, Inc. |
ANTI-SARS-CoV-2 ANTIGEN-BINDING POLYPEPTIDES, POLYPEPTIDE COMPLEXES AND THEIR METHODS OF USE
|
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
|
EP4598958A1
(en)
|
2022-10-05 |
2025-08-13 |
Amgen Inc. |
Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
|
|
TW202440633A
(zh)
|
2023-03-08 |
2024-10-16 |
美商安進公司 |
用於雙特異性分子的控制冰成核凍乾方法
|
|
AU2024302269A1
(en)
|
2023-06-14 |
2025-11-13 |
Amgen Inc. |
T cell engager masking molecules
|
|
TW202506719A
(zh)
|
2023-07-27 |
2025-02-16 |
德商艾瑪提克生物技術有限公司 |
針對mageb2之抗原結合蛋白
|
|
AU2024329520A1
(en)
|
2023-08-22 |
2026-01-29 |
Amgen Inc. |
Methods and assemblies for efficiently packing pharmaceutical products
|
|
WO2025101672A1
(en)
|
2023-11-06 |
2025-05-15 |
City Of Hope |
Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers
|
|
WO2025226901A1
(en)
|
2024-04-25 |
2025-10-30 |
Amgen Inc. |
Pairing of two-chain constructs
|
|
WO2025233432A1
(en)
|
2024-05-07 |
2025-11-13 |
Immatics Biotechnologies Gmbh |
Use and dosage of an antigen-binding protein comprising a tcr specific for an hla-a*02 restricted peptide
|
|
WO2025257588A1
(en)
|
2024-06-10 |
2025-12-18 |
Affimed Gmbh |
Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance
|
|
WO2025259515A2
(en)
|
2024-06-11 |
2025-12-18 |
Amgen Inc. |
Combination treatment
|
|
WO2026025031A1
(en)
|
2024-07-26 |
2026-01-29 |
Modernatx, Inc. |
Mrna encoding mageb2 tcer molecule
|